IL287673B1 - Process for preparing xpo1 inhibitors and intermediates for use in preparing xpo1 inhibitors - Google Patents

Process for preparing xpo1 inhibitors and intermediates for use in preparing xpo1 inhibitors

Info

Publication number
IL287673B1
IL287673B1 IL287673A IL28767321A IL287673B1 IL 287673 B1 IL287673 B1 IL 287673B1 IL 287673 A IL287673 A IL 287673A IL 28767321 A IL28767321 A IL 28767321A IL 287673 B1 IL287673 B1 IL 287673B1
Authority
IL
Israel
Prior art keywords
structural formula
compound represented
iii
conditions suitable
produce
Prior art date
Application number
IL287673A
Other languages
English (en)
Hebrew (he)
Other versions
IL287673A (en
Original Assignee
Karyopharm Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karyopharm Therapeutics Inc filed Critical Karyopharm Therapeutics Inc
Publication of IL287673A publication Critical patent/IL287673A/en
Publication of IL287673B1 publication Critical patent/IL287673B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL287673A 2019-05-01 2021-10-28 Process for preparing xpo1 inhibitors and intermediates for use in preparing xpo1 inhibitors IL287673B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962841649P 2019-05-01 2019-05-01
PCT/US2020/031124 WO2020223678A1 (en) 2019-05-01 2020-05-01 Process for preparing xpo1 inhibitors and intermediates for use in the preparation of xp01 inhibitors

Publications (2)

Publication Number Publication Date
IL287673A IL287673A (en) 2021-12-01
IL287673B1 true IL287673B1 (en) 2026-01-01

Family

ID=70802955

Family Applications (1)

Application Number Title Priority Date Filing Date
IL287673A IL287673B1 (en) 2019-05-01 2021-10-28 Process for preparing xpo1 inhibitors and intermediates for use in preparing xpo1 inhibitors

Country Status (14)

Country Link
US (1) US12479806B2 (cg-RX-API-DMAC7.html)
EP (1) EP3962898A1 (cg-RX-API-DMAC7.html)
JP (2) JP7630444B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220004142A (cg-RX-API-DMAC7.html)
CN (1) CN114040909B (cg-RX-API-DMAC7.html)
AU (1) AU2020266170B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021021706A2 (cg-RX-API-DMAC7.html)
CA (1) CA3135712A1 (cg-RX-API-DMAC7.html)
CR (1) CR20210590A (cg-RX-API-DMAC7.html)
IL (1) IL287673B1 (cg-RX-API-DMAC7.html)
MA (1) MA55808A (cg-RX-API-DMAC7.html)
MX (1) MX2021013211A (cg-RX-API-DMAC7.html)
SG (1) SG11202111993SA (cg-RX-API-DMAC7.html)
WO (1) WO2020223678A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114040909B (zh) 2019-05-01 2025-06-03 卡尔约药物治疗公司 用于制备xpo1抑制剂以及用于制备xp01抑制剂的中间体的方法
JP2021048976A (ja) * 2019-09-24 2021-04-01 株式会社ユニバーサルエンターテインメント 遊技機
CN112679477B (zh) * 2020-12-17 2021-10-26 佛山奕安赛医药科技有限公司 塞利尼索及其中间体的制备方法
CN116514773B (zh) * 2023-04-24 2024-12-03 重庆汉佩生物科技有限公司 一种Verdinexor(KPT-335)及其盐酸盐的合成方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013170068A2 (en) * 2012-05-09 2013-11-14 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
WO2014205393A1 (en) * 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
WO2016025904A1 (en) * 2014-08-15 2016-02-18 Karyopharm Therapeutics Inc. Polymorphs of selinexor
WO2017118940A1 (en) * 2016-01-08 2017-07-13 Dr. Reddy's Laboratories Limited Solid forms of selinexor and process for their preparation
WO2018129227A1 (en) * 2017-01-05 2018-07-12 Watson Laboratories Inc. Novel crystalline forms of selinexor and process for their preparation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2542089B1 (en) 2010-03-05 2017-01-18 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
EP2665362B1 (en) 2011-01-17 2016-03-30 Karyopharm Therapeutics, Inc. Olefin containing nuclear transport modulators and uses thereof
EP4234545A3 (en) 2011-07-29 2023-09-06 Karyopharm Therapeutics Inc. Hydrazide containing nuclear transport modulators and uses thereof
JP6006794B2 (ja) 2011-07-29 2016-10-12 カリオファーム セラピューティクス,インコーポレイテッド 核内輸送調節因子およびその使用
EP2968278B8 (en) 2013-03-15 2019-05-22 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
ME03421B (me) 2013-06-21 2020-01-20 Karyopharm Therapeutics Inc 1,2,4-triazoli kao modulatori nuklearnog transporta i njihova upotreba
US10526295B2 (en) 2015-12-31 2020-01-07 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
EP3397634A1 (en) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
CN114040909B (zh) 2019-05-01 2025-06-03 卡尔约药物治疗公司 用于制备xpo1抑制剂以及用于制备xp01抑制剂的中间体的方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013170068A2 (en) * 2012-05-09 2013-11-14 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
WO2014205393A1 (en) * 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
WO2016025904A1 (en) * 2014-08-15 2016-02-18 Karyopharm Therapeutics Inc. Polymorphs of selinexor
WO2017118940A1 (en) * 2016-01-08 2017-07-13 Dr. Reddy's Laboratories Limited Solid forms of selinexor and process for their preparation
WO2018129227A1 (en) * 2017-01-05 2018-07-12 Watson Laboratories Inc. Novel crystalline forms of selinexor and process for their preparation

Also Published As

Publication number Publication date
AU2020266170A1 (en) 2021-11-25
US20220242832A1 (en) 2022-08-04
CR20210590A (es) 2022-03-11
JP2025072490A (ja) 2025-05-09
JP2022531576A (ja) 2022-07-07
JP7850834B2 (ja) 2026-04-23
CA3135712A1 (en) 2020-11-05
WO2020223678A1 (en) 2020-11-05
US12479806B2 (en) 2025-11-25
MX2021013211A (es) 2022-03-11
SG11202111993SA (en) 2021-11-29
EP3962898A1 (en) 2022-03-09
MA55808A (fr) 2022-03-09
JP7630444B2 (ja) 2025-02-17
CN114040909A (zh) 2022-02-11
IL287673A (en) 2021-12-01
BR112021021706A2 (pt) 2022-04-19
KR20220004142A (ko) 2022-01-11
AU2020266170B2 (en) 2026-02-26
CN114040909B (zh) 2025-06-03

Similar Documents

Publication Publication Date Title
IL287673B1 (en) Process for preparing xpo1 inhibitors and intermediates for use in preparing xpo1 inhibitors
AU2014339136B2 (en) Process for the preparation of a PDE4 inhibitor
JP6873053B2 (ja) タンパク質脱アセチル化阻害剤の製造方法
JP2023523219A (ja) モノアシルグリセロールリパーゼ阻害剤の合成
WO2001025185A1 (en) Process for the preparation of a piperazine derivative
EP2935255A1 (en) A process for preparation of rivaroxaban
CA3000580A1 (en) Maleic acid salt of a silodosin intermediate
JP2021515018A (ja) 可溶性グアニル酸シクラーゼ刺激薬を調製するための方法
JP7583398B2 (ja) タウロデオキシコール酸ナトリウムの大量生産方法
JP7777527B2 (ja) (9S)-2-ブロモ-9-(2,3,4-トリフルオロフェニル)-6,7,8,9-テトラヒドロ-5H-[1,2,4]トリアゾロ[1,5-a]アゼピンの製造方法
CA3208267A1 (en) Methods for producing of lipids
JP2009525964A (ja) 6,7−ジヒドロ−5H−イミダゾ[1,2−a]イミダゾール−3−スルホン酸アミドの合成
JP2022543057A (ja) 結晶形iiのソタグリフロジンを調製する方法
IL280312B1 (en) A process for making bromodomain inhibitors
CN115894525B (zh) 一种氯诺昔康中间体的合成方法
EP4685237A1 (en) Process and intermediates for the preparation of etrasimod and related compounds
CN110423215B (zh) 一种查尔酮吡啶盐及其制备方法和应用
WO2024224298A1 (ko) 4-아미노인단의 제조 방법 및 디하이드로인데닐-피라졸로[3,4-b]피리딘 아민 화합물의 제조 방법
EA052667B1 (ru) Синтез дироксимелфумарата
CN115368283A (zh) 一种手性结构或非手性结构的顺式-3-氟-4-羟基吡咯烷及其衍生物的制备方法
CN118546091A (zh) 一种5-乙酰基-1h-吡唑-3-羧酸及其制备方法和应用
TW202219027A (zh) 取代的丙烯酸酯化合物的製備
HK40062367A (en) Process for preparing the crystalline form ii of sotagliflozin
CN113214321A (zh) 一种米诺膦酸e晶型的制备方法
US20040069208A1 (en) Process for crystallizing enantiomerically enriched 2-acetylthio-3-phenylpropionic acid